TABLE 2

Survival After ¹⁸⁶Re-HEDP Therapy

Patient no.	Response to treatment	Survival after diagnosis of metastatic disease (mo)	Survival after last ¹⁸⁶Re HEDP therapy (mo)	Site of metastases	Subsequent therapy	Follow-up
1	Stable disease: biopsy negative	216	60	Lung	None	Disease-free
2	Stable disease	48	10	Lung	EBRT	Died: perforated bowel
3	Stable disease	36	10	Lung	Ifosfamide; palliative EBRT^*	Poor hematologic tolerance of oral etoposide given for palliation; died of gastrointestinal hemorrhage 3 mo after final ¹⁸⁶Re-HEDP dose
4	Stable disease	48	1	Lung	Supportive/EBRT	Poor pain control; died at 6 mo
5	Stable disease	12	1	Lung	Supportive^†/EBRT	Died at 5 mo: progressive lung disease
6	Stable disease	36	2	Scapula/sternum/thoracic spine	Supportive^†/EBRT	Poor pain control: died
7	Lost to follow-up	NA	NA	Lung	EBRT	Lost to follow-up at 3 mo
8	Progressive disease	45	36	Lung/femoral/iliac lymph nodes	Palliative/EBRT	Died at 1 mo of hepatic progression; platelets and white blood cells normal
9	Pain relief at 2 sites but not at third by 1 mo	12	4	Lung/bone	Supportive/EBRT	Died of progressive disease 12 mo after first ¹⁸⁶Re-HEDP dose
10	Progressive disease	96	13	Lung	Palliative EBRT 3 mo	Died
11	Progressive disease	36	5	Lung	Palliative EBRT 2 mo	Died at 36 mo
12	No pain relief	20	6	Lung	Supportive/EBRT	Died at 24 mo
13	Progressive disease	30	2	Lung	Palliative EBRT to 1 site at 1 mo	Died